This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; Quotes are being requested and a separate written solicitation will not be issued.
The solicitation number is 75N95024Q00433 and the solicitation is issued as request for quotation (RFQ).
This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; and FAR Part 12—Acquisition of Commercial Items and is not expected to exceed the simplified acquisition threshold.
The NeuroTherapeutics Development Unit (NTDU) Translational Neuroscience (TNC) National Institute of Neurological Disorders and Stroke (NINDS) requires the purchase of a high throughput cell analysis system with equivalent capabilities to the Agilent xCELLigence RTCA HT system to facilitate the screening and evaluation of toxicities to neurons and other cells following exposure to chemotoxic agents, toxic proteins and viral infections.
The mission of the Translational Neuroscience Center, TNC/ Neurotherapeutic Development Unit (NTDU), is to identify, characterize and develop new therapeutic agents to treat neuro degeneration and infectious diseases in the human brain. Currently NTDU utilizes many modalities to develop new therapeutic agents, many of the models involve cell toxicity and different assays to determine the toxic activity of chemicals, proteins and viral infections. A novel approach is to incorporate the real time cell analysis provided by the xCELLigence RTCA HT system to facilitate compound screening in 384 well plate format. High-throughput real-time cell analysis is ideal for screening viral mediated cytopathic effects (CPE), neutralizing antibodies, antibody-dependent cytotoxicity (ADCC), and compound mediated cytotoxicity. The system will be used to quantitate the cell types following exposure to toxic chemicals, proteins, patient serum/plasma or cerebrospinal fluid or viral infections. The NTDU require the acquisition of an equivalent system to the xCELLigence RTCA HT system, consisting of an xCELLigence RTCA SP analyzer and Biospag-SN automated incubator with associated peripherals and software compatible with pre-existing instruments to develop new therapeutic agents, to treat neuro degeneration and infectious diseases in the human brain.
This is a Brand Name or Equal requirement for an xCELLigence RTCA SP System with automated incubator and associated peripherals. The contractor must provide a system with equivalent capabilities to the following:
- The xCELLigence RTCA SP, which analyzes live cells in a 384-well format. Comes bundled with analyzer, plate station, and control unit with software, cat# 380601070
- Automated incubator with 8-plate capacity, incubation to 45degC, and CO2 /O2 control and monitoring, water pan and humidity monitoring. Incl. BioSpa software and one alignment kit. Rep. BTI no. BIOSPAG, cat# Biospag-SN
- ACCESS FLUIDICS ALIGN, Cat# 1410011
- RTCA-HT BioSpa Integration package, cat# S2812AA
